



350 - 4243 Glanford Ave.
Victoria, BC Canada V8Z 4B9
Tel: (250) 744-2811 Fax: (250) 744-2877
<http://www.stressgen.com>

00/01

Contact:

David Matthews
StressGen Biotechnologies
(250) 744-2811

Gretchen L. P. Schweitzer OR
Feinstein Kean Partners
(617) 577-8110

Fran DeVellis
Feinstein Kean Partners
(617) 577-8110

FOR IMMEDIATE RELEASE

StressGen Introduces New Hsp70 Immunoassay Kit for Researchers

Victoria, British Columbia, January 10, 2000 –StressGen Biotechnologies Corp. (TSE: SSB) today announced the launch of the first commercial Immunoassay (EIA) kit for the measurement of heat shock protein 70 (Hsp70) in a variety of species and sample types. The kit includes all components required to obtain reliable, consistent results quickly and easily, it can detect minute quantities of Hsp70 in samples in under 4.5 hours. It is currently available for \$650.00 US.

"We are very proud to offer this product, which is the first commercially available EIA kit for the detection and quantification of Hsp70 in cell lysates and tissue extracts," said Henry Rodriguez, Vice President of StressGen's Biochemical division. "We have overcome significant technical problems associated with the accurate measurement of Hsp70 in complex samples which has allowed us to develop a kit which has many advantages over traditional measurement procedures. This kit provide researchers with a method to easily and quickly measure the levels of Hsp70 in the numerous samples necessary to further define the role Hsp70 plays in critical cellular processes. Information from such studies has the potential of implicating Hsp70 as a diagnostic tool to evaluate and monitor a variety of diseases."

"StressGen's Biochemicals division has experienced sales growth of over 20% per year over the past four years," said Richard M. Glickman, StressGen's President and Chief Executive Officer. "We are very excited about the potential of this kit along with other new product introductions to continue and accelerate this strong sales growth"

Hsp70 can protect other proteins and repair damaged proteins in response to cellular stress caused by environmental stressors, pathogens, and disease. Hsp70 is essential for cellular recovery, survival and maintenance of normal cellular function. In most mammals, the production of Hsp70 is increased in response to exposure to stress. Current research is aimed at exploiting Hsp70's cellular protective abilities as a therapeutic strategy against damaging cellular stress.

The role of Hsp70 has been studied in a variety of medically relevant models or conditions such as hypothermia, hypertension, toxic exposure to chemical agents, hypoxia, ischemia, inflammation, autoimmunity, apoptosis, cancer, organ transplantation, bacterial and viral infections. Hsp70 has also been studied in normal biological processes such as aging, spermatogenesis, menstruation and exercise.

MORE . . .

StressGen Introduces New Hsp70 Immunoassay Kit for Researchers

Page 2

StressGen Biotechnologies Corp. is a biopharmaceutical company developing innovative immunotherapy products to treat cancer and prevent infectious disease. The Company's core technology capitalizes on the ability of stress proteins to activate the body's immune system to recognize and fight disease. Through its Biochemical Division, StressGen is also an internationally recognized supplier of stress protein, apoptosis, cell proliferation, protein phosphorylation, receptors and neuroscience research products. These products are used by scientists worldwide.

The matters contained in this news release including, but not limited to clinical trials, regulatory matters, beliefs, and expectations are forward-looking statements. StressGen undertakes no obligation to publicly release the results of any revision to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

###